Analyzer Automates Cell-Culture Chemistry Analysis
The BioProfile FLEX 2 from Nova Biomedical is a cell-culture chemistry analyzer that allows for automated cell-culture analysis for small-volume culture systems.
The BioProfile FLEX 2 from Nova Biomedical is a cell-culture chemistry analyzer that allows for automated cell-culture analysis for small-volume culture systems. The system incorporates Nova’s MicroSensor Card technology, which minimizes sensor maintenance. The FLEX 2 provides analysis of 16-cell culture chemistries including Gluc, Lac, Gln, Glu, NH4+, Na+, K+, Ca++, pH, pCO2, pO2, osmolality by freezing point depression, and total and viable cell density and viability by trypan blue dye exclusion method. The full panel of tests can be run in under four minutes with 265 microliters of sample, and users can select from manual sampling or two modes for batch sampling: 96-well plates or the built-in 24-position tray. Designed for small volume, early-stage cell culture development through GMP manufacturing, BioProfile FLEX 2 provides 21 CFR Part 11 compliance, OPC connectivity, full networking functionality, and support with all validation needs.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
